Nanoparticle Formulation Market Report 2025, with Profiles of Ascension Sciences, DIANT Pharma, ExonanoRNA, Nanoform, NanoVation Therapeutics, NanoVelos, NTT Biopharma, Organoid-X BioTech, & Vaxinano – ResearchAndMarkets.com




Nanoparticle Formulation Market Report 2025, with Profiles of Ascension Sciences, DIANT Pharma, ExonanoRNA, Nanoform, NanoVation Therapeutics, NanoVelos, NTT Biopharma, Organoid-X BioTech, & Vaxinano – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Nanoparticle Formulation Market Industry Trends and Global Forecasts to 2035, by Type of Nanoparticle, Scale of Operation and Key Geographical Regions” report has been added to ResearchAndMarkets.com’s offering.

The global nanoparticle formulation market is estimated to grow from USD 5.1 billion in 2025, to USD 15.1 billion by 2035, at a CAGR of 9.4% during the forecast period to 2035.

Nanoparticle Formulation Market: Growth and Trends

Having demonstrated a strong therapeutic potential across a myriad of diseases, nanoparticle-based drugs have emerged as a promising treatment alternative within a short span. In fact, given the current ongoing pace of research, experts believe that remarkable innovations in the field of nanoparticles (in terms of improvement in disease diagnosis and treatment specificity) are likely to revolutionize the pharma industry in the coming years. Furthermore, the recent initiatives focused on nanotechnology for the detection and control of vector-borne diseases, dialysis, and molecular imaging, have further fueled the demand for these nanoparticles.

In addition, the nanoparticles can be engineered to achieve optimal delivery and overcome the limitations of biological barriers (systemic, microenvironmental and cellular) in the patient’s body owing to their modifiable properties (such as size, shape, surface properties and charge). However, the complex interplay between nanoparticle properties and biological systems requires careful consideration to ensure the safety and efficacy of these nanoscale materials. Various stakeholders, such as contract research organizations, (CROs), and contract development and manufacturing organizations (CDOs / CDMOs) are likely to play a pivotal role in supporting researchers and drug developers to navigate the complexities associated with its design, development and manufacturing.

By leveraging the multifaceted expertise in the field, contract service providers can help streamline the nanoparticle development process, reduce costs, and accelerate the translation of promising nanoparticles from lab scale to clinical scale. Driven by technological advancements and the rising demand for nanoparticle-based drugs, the nanoparticle formulation services market is anticipated to witness notable growth in the foreseen future.

Nanoparticle Formulation Market: Key Insights

The report delves into the current state of the nanoparticle formulation market and identifies potential growth opportunities within the industry.

Some key findings from the report include:

• Presently, more than 100 nanoparticle formulation technologies are being offered by companies across the globe in order to augment the development and manufacturing of nanoparticle-based drugs.
• Close to 80% of technologies are designed for the formulation of organic nanoparticles; of these, nearly 50% are intended for drug delivery via injectable route, primarily targeting oncological disorders.
• The current service providers landscape has over 80 companies offering a wide range of nanoparticle formulation services at various scales of operation.
• The market landscape features the presence of both well-established players and new entrants with the requisite expertise to develop / manufacture nanoparticle-based drugs for an extensive range of application areas.
• Owing to the rise in demand for nanoparticle-based formulations, service providers are continuously expanding their existing capabilities to enhance their respective service portfolios.
• A steady growth in the partnership activity has been observed in recent years; R&D agreements have been the most prominent type of partnership model adopted by players based in the US.
• More than 1,700 patents related to nanoparticle formulation and development have been filed by / granted to various organizations in order to protect intellectual property.
• The nanoparticle formulation services market is likely to grow at a CAGR of ~9% over the next decade, driven by revenues generated from commercial scale operation.

Nanoparticle Formulation Market: Key Segments

Organic Nanoparticles are Likely to Dominate the Nanoparticle Formulation Market During the Forecast Period

Based on the type of nanoparticle, the market is segmented into organic nanoparticles, inorganic nanoparticles and carbon-based nanoparticles. At present, organic nanoparticles hold the maximum share of the nanoparticle formulation market. This trend is unlikely to change in the near future.

Protein-based Nanoparticles Segment is the Fastest Growing Segment of the Nanoparticle Formulation Market During the Forecast Period

Based on the type of organic nanoparticle, the market is segmented into polymeric nanoparticles, lipid nanoparticles, viral nanoparticles, protein-based nanoparticles, and other organic nanoparticles. It is worth highlighting that, currently, lipid nanoparticles hold a larger share of the nanoparticle formulation market. However, the nanoparticle formulation market for protein-based nanoparticles is likely to grow at a higher CAGR in the coming decade.

Commercial Operations Occupy the Largest Share of the Nanoparticle Formulation Market

Based on scales of operation, the market is segmented into preclinical, clinical and commercial scales. At present, commercial operations capture the maximum share of the nanoparticle formulation market. It is worth highlighting that the nanoparticle formulation market at the clinical scale is likely to grow at a higher CAGR in the near future.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the world. The majority share is expected to be captured by service providers based in North America and Europe. It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.

Sample Players in the Nanoparticle Formulation Market, Profiled in the Report

• Ascension Sciences
• DIANT Pharma
• ExonanoRNA
• Nanoform
• NanoVation Therapeutics
• NanoVelos
• NTT Biopharma
• Organoid-X BioTech
• Vaxinano

Nanoparticle Formulation Market: Research Coverage

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the nanoparticle formulation market, focusing on key market segments, including type of nanoparticle formulated, type of organic nanoparticle formulated, scale of operation and key geographical regions.
• Market Landscape 1: A comprehensive evaluation of nanoparticle formulation technologies, considering various parameters, such as type of nanoparticle(s) formulated, type of molecule(s) delivered, therapeutic area(s), compatible dosage form(s) and route(s) of administration. Further, the chapter provides information on various technology developers, along with analysis based on multiple parameters, such as year of establishment, company size, location of headquarters and most active players (in terms of number of technologies developed).
• Market Landscape 2: A comprehensive evaluation of nanoparticle formulation service providers, considering various parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, location of facilities, type of service provider(s), type of nanoparticle(s) formulated, type of service(s) offered, scale of operation and application area(s).
• Technology Competitiveness: A comprehensive competitive analysis of nanoparticle formulation technologies, examining factors, such as developer power, technology strength and technology applicability.
• Company Competitiveness: A comprehensive competitive analysis of nanoparticle formulation service providers, examining factors, such as company strength and service strength.
• Company Profiles: In-depth profiles of key industry players offering technologies and services for nanoparticle formulation across North America, Europe and Asia-Pacific, focusing on company overviews, technology portfolio, service portfolio, recent developments and an informed future outlook.
• Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2018, covering technology licensing agreements, research and development agreements, product development agreements, manufacturing agreements, mergers and acquisitions, technology integration agreements and other relevant agreements.
• Patent Analysis: Detailed analysis of various patents filed / granted related to nanoparticle formulation based on publication year, geographical region, CPC symbols, leading players (in terms of number of patents filled / granted) and type of organization. It also includes a patent benchmarking analysis and a detailed valuation analysis.
• Nanoparticle Evaluation Framework: An insightful framework evaluating types of nanoparticles based on various parameters, such as number of technologies, nanoparticle efficacy, number of clinical trials evaluating nanoparticle-based drugs, extent of innovation, trends in research activity and current global competition. It also provides a value addition matrix for respective types of nanoparticles currently adopted by stakeholders.
• Case Study: A case study of the recent technology licensing agreements, along with information on deal amounts.

Key Questions Answered in this Report

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What kind of partnership models are commonly adopted by industry stakeholders?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team

For more information about this report visit https://www.researchandmarkets.com/r/uh9gwr

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Digital Biomarkers Global Markets Report 2025-2030 with Profiles of Leading Players – Actigraph, AliveCor, Altoida, Evidation Health, and IXICO – ResearchAndMarkets.com




Digital Biomarkers Global Markets Report 2025-2030 with Profiles of Leading Players – Actigraph, AliveCor, Altoida, Evidation Health, and IXICO – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Digital Biomarkers: Global Markets” report has been added to ResearchAndMarkets.com’s offering.

The global market for digital biomarkers is estimated to grow from $5 billion in 2025 to $18.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 30.4% from 2025 through 2030.

This report provides an overview of the global market for digital biomarkers and analyzes market trends. It includes global revenue ($ millions) for the base year data of 2024, estimates for 2025 and projections of compound annual growth rates (CAGRs) from 2025 through 2030. The market is segmented based on system components, applications, therapeutic areas, end users and regions. The regions covered in this study include North America, Europe, Asia-Pacific and the Rest of the World (RoW), focusing on major countries in these regions.

The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It analyzes environmental, social and governance (ESG) developments and discusses emerging technologies related to the market.

The report includes:

• 53 data tables and 54 additional tables
• An overview of the global market for digital biomarkers
• Estimation of the market size and analyses of global market trends, with data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
• Information regarding major market drivers, opportunities and challenges, industry chain structure, distribution channel and technological advancements that are affecting the overall market
• Evaluation of market potential and revenue forecast for the digital biomarkers market based on system component, application, therapeutic area, end user and region
• Insights into the industry structure, current competitive scenario, R&D activities, growth strategies and ESG trends of the market
• Identification of companies best positioned to meet this demand due to their proprietary technologies, mergers and acquisitions, joint ventures and strategic alliances
• Profiles of the leading companies, including Actigraph LLC., AliveCor Inc., Altoida, Evidation Health Inc., and IXICO Plc.

Company Profiles

• Actigraph LLC.
• Akili Inc.
• Alivecor Inc.
• Altoida
• Embic Corp.
• Empatica Inc.
• Evidation Health Inc.
• Feel Therapeutics
• Huma
• Ixico PLC
• Kinsa Inc.
• Koneksa Health
• Neurotrack Technologies Inc.
• Vivosensmedical GmbH
• Winterlight Labs

Key Attributes:

Key Topics Covered:

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Overview and Market Definition
• Digital Biomarker Types
• Comparison of Traditional and Digital Biomarkers
• Pestel Analysis
• Political
• Economic
• Social
• Technological
• Environmental
• Legal
• Impact of U.S. Tariff Laws on the Digital Biomarkers Market
• Increase in Product Costs
• Effects on Supply Chain
• Opportunities for Local Production
• Conclusion

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Rising Adoption of Mhealth Apps and Wearables
• Growing Application of Digital Biomarkers in Neurodegenerative and Psychiatric Disorders
• Increasing Role of Digital Biomarkers in Clinical Trials
• Corporate Wellness Programs and Incentives
• Market Restraints
• Data Standardization and Interpretation Issues
• Difficulties in Validation of Biomarkers
• Data Privacy and Protection
• Market Opportunities
• Growing Technology Innovations
• Increasing Research Collaborations and Partnerships

Chapter 4 Regulatory Landscape

• Regulatory Scenario
• The U.S.
• Canada
• Europe
• Asia-Pacific

Chapter 5 Emerging Technologies and Developments

• Artificial Intelligence-based Digital Biomarkers
• Enhancement of Digital Biomarkers by AI and ML
• Benefits of AI-Driven Digital Biomarkers

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Market Breakdown by System Component
• Key Takeaways
• Data Collection Tools
• Data Integration Systems
• Market Breakdown by Application
• Key Takeaways
• Diagnostic Digital Biomarkers
• Monitoring Digital Biomarkers
• Predictive Digital Biomarkers
• Other Applications
• Market Breakdown by Therapeutic Area
• Key Takeaways
• Cardiovascular and Metabolic Disorders
• Psychiatric Disorders
• Neurological Disorders
• Musculoskeletal Disorders
• Respiratory Disorders
• Other Therapeutic Areas
• Market Breakdown by End-user
• Key Takeaways
• Pharmaceutical Companies and Research Institutions
• Healthcare Providers
• Patients and Caregivers
• Employers
• Payers
• Geographic Breakdown
• Market Breakdown by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Competitive Intelligence

• Key Takeaways
• Prominent Digital Biomarkers Companies
• Competitor Types and Their Strategies
• Pharmaceutical Companies
• Large Technology Companies
• Small and Medium-Size Technology Companies
• Strategic Analysis
• Agreements, Collaborations and Partnerships
• New Product Launches
• Acquisitions and Mergers
• Regulatory Approvals

Chapter 8 Sustainability in Digital Biomarkers Market: ESG Perspective

• Introduction
• Sustainability Factors
• Environmental Sustainability
• Social Sustainability
• Economic Sustainability
• Other Factors
• Scaling Sustainable Practices in Healthcare
• Business Practices Implementing Sustainable Solutions
• Conclusion

Chapter 9 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/sz3yzs

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

STAT Inhibitors Pipeline Market Insights Report 2025 | 18 Companies and 22 Pipeline Drugs in Stages Ranging from Clinical to Nonclinical – ResearchAndMarkets.com




STAT Inhibitors Pipeline Market Insights Report 2025 | 18 Companies and 22 Pipeline Drugs in Stages Ranging from Clinical to Nonclinical – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “STAT Inhibitors – Pipeline Insight, 2025” has been added to ResearchAndMarkets.com’s offering.

The “STAT Inhibitors – Pipeline Insight, 2025” report offers exhaustive insights into the emerging landscape of STAT Inhibitors, with over 18 companies and 22 pipeline drugs in stages ranging from clinical to nonclinical. The report delves into the therapeutic assessment categorized by product type, stage, route of administration, and molecular type, while also illustrating inactive pipeline products.

Signal Transducer and Activator of Transcription (STAT) inhibitors are pivotal in targeting aberrant STAT signaling, especially involving STAT3 and STAT5, which are linked to diverse diseases like cancers and inflammatory disorders. These inhibitors aim to disrupt the pathological cell behaviors associated with these conditions. Current research underscores their potential in targeted applications, predominantly in oncology and chronic inflammatory diseases.

STAT proteins, encompassing seven members, function as signal transducers directly influencing gene expression. Each protein plays distinct roles, with STAT1 crucial for antiviral responses, STAT3 extensively involved in oncogenesis, and STAT6 impacting immune regulations. Their structural design, comprising domains like the SH2 domain, facilitates signal transduction and transcriptional regulation. Stat proteins’ therapeutic targeting continues to be significant in oncology, autoimmune disorders, and as potential biomarkers for disease progression and treatment efficacy.

The “STAT Inhibitors – Pipeline Insight, 2025” report presents an in-depth look into the current scenario and growth prospects for these inhibitors. It features a detailed landscape of the STAT Inhibitors pipeline, including disease overviews and treatment guidelines, while thoroughly assessing the commercial and clinical facets of ongoing developments.

The report highlights leading drugs in development, providing insights into their mechanisms, clinical trials, approvals, and technological collaborations. Notably, TTI-101 from Tvardi Therapeutics, in Phase II trials, has shown promise against conditions like liver and breast cancer. Similarly, Kymera Therapeutics’ KT-621, a standout oral STAT6 degrader, is in Phase I trials for Atopic Dermatitis, showcasing superior preclinical efficacy. Vividion’s VVD-850, another STAT3 inhibitor, underpins broad cancer applications, currently in early Phase I trials.

A key component of the report is the therapeutic assessment, segmented by various parameters such as clinical stages including Phase III, II, I, preclinical, and discovery stages. Drugs are further categorized by their route of administration, product types, and molecular forms. Active collaborations, mergers, acquisitions, licensing activities, and narrative on clinical studies anchor the comprehensive view presented.

The report canvasses key players like Tvardi Therapeutics, Kymera Therapeutics, Bayer, and Vividion, among others, who are advancing the frontier of STAT Inhibitor research and development.

In summary, the STAT Inhibitors report encapsulates a robust analysis of the pipeline, therapeutic potential, and identifies current unmet needs in the market. It serves as a crucial guide for stakeholders witnessing the evolving capacities of STAT-targeted therapies across various medical disciplines.

Key Topics Covered:

Introduction

Executive Summary

STAT Inhibitors: Overview

• Introduction
• Structure
• Function
• Mechanism of action
• STAT Inhibitors as therapeutic target

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

STAT Inhibitors – Analytical Perspective

Late Stage Products (Phase III)

• Product Description
• Research and Development
• Product Development Activities

Mid Stage Products (Phase II)

• Comparative Analysis

TTI-101: Tvardi Therapeutics

• Product Description
• Research and Development
• Product Development Activities

Early Stage Products (Phase I)

• Comparative Analysis

VVD-850: Vividion Therapeutics

• Product Description
• Research and Development
• Product Development Activities

Preclinical and Discovery Stage Products

• Comparative Analysis

STAT Inhibitors Key Companies

STAT Inhibitors Key Products

STAT Inhibitors – Unmet Needs

STAT Inhibitors – Market Drivers and Barriers

STAT Inhibitors – Future Perspectives and Conclusion

STAT Inhibitors Analyst Views

STAT Inhibitors Key Companies

• Tvardi Therapeutics
• Kymera Therapeutics, Inc
• Vividion Therapeutics
• Bayer
• Moleculin
• Purple Biotech
• LEO Pharma
• Enanta Pharmaceuticals
• Kaken Pharmaceutical
• Astrazeneca
• Arrakis Therapeutics
• Accendatech
• JW Pharmaceutical
• Recludix

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/psf77e

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Non Muscle Invasive Bladder Cancer Pipeline Insight Report 2025 | Phase III Clinical Trials – Promising New Drug Developments – ResearchAndMarkets.com




Non Muscle Invasive Bladder Cancer Pipeline Insight Report 2025 | Phase III Clinical Trials – Promising New Drug Developments – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Non Muscle Invasive Bladder Cancer – Pipeline Insight, 2025” has been added to ResearchAndMarkets.com’s offering.

The “Non Muscle Invasive Bladder Cancer – Pipeline Insight, 2025” report provides a thorough examination of the pipeline landscape for Non Muscle Invasive Bladder Cancer (NMIBC), engaging with over 20 companies and 22 plus pipeline drugs. This report details both clinical and non-clinical stage products, offering insights into therapeutic assessments by product type, stage, and route of administration. Pipeline inactivity is also highlighted.

Non-muscle invasive bladder cancer remains predominantly confined to the bladder wall’s inner layers, manifesting in stages such as Ta, T1, and carcinoma in situ (CIS). It represents about 70-80% of newly diagnosed cases with a high recurrence rate but lower progression risk. Essential management strategies include TURBT followed by intravesical therapies. Regular cystoscopic surveillance is crucial due to high recurrence probabilities.

Therapeutics in development are pioneering novel treatment prospects. Cretostimogene grenadenorepvec from CG Oncology is an oncolytic immunotherapy in Phase III, focusing on tumor-selective replication and immune response amplification. TAR-210 by Janssen Research & Development offers an innovative drug delivery system targeting FGFR alterations. In Phase II, Tyra Biosciences’ TYRA-300 is assessed as an FGFR3-selective inhibitor. UGN-301, from UroGen Pharma Ltd., is an anti-CTLA-4 monoclonal antibody explored in a Phase I study for its effectiveness in maintaining local drug concentrations with reduced systemic exposure.

A comprehensive therapeutic assessment provided in the report classifies drugs by development stages: Phase III, II, I, Preclinical, and Discovery. Various routes of administration such as oral, intravenous, and intravesical are considered, alongside molecule types like small molecules, monoclonal antibodies, and gene therapies.

The report identifies significant players like CG Oncology and Tyra Biosciences, and delves into their pipeline activities, including collaborations, mergers, and licensing. Novel developments like small, bladder-resident devices or selective inhibitors show promising management avenues for NMIBC, especially for patients resistant to traditional therapies like BCG.

A detailed analysis covers emerging drugs, their clinical trial stages, and innovative pharmacological actions. This report highlights unmet needs, advances in drug types, and key designations granted to emerging therapies, positioning it as an essential resource for stakeholders aiming to navigate NMIBC treatment breakthroughs.

For further exploration and insights into NMIBC’s therapeutic landscape, major players such as CG Oncology, Janssen Research & Development, Tyra Biosciences, UroGen Pharma, and others continue to drive the R&D sphere, adapting strategic measures to improve treatment efficacy and patient outcomes by 2025.

Key Topics Covered:

Introduction

Executive Summary

Non Muscle Invasive Bladder Cancer: Overview

• Introduction
• Causes
• Pathophysiology
• Signs and Symptoms
• Diagnosis
• Treatment

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Non Muscle Invasive Bladder Cancer – Analytical Perspective

Late Stage Products (Phase III)

• Comparative Analysis

Cretostimogene grenadenorepvec: CG Oncology

• Product Description
• Research and Development
• Product Development Activities

Mid Stage Products (Phase II)

• Comparative Analysis

TYRA-300: Tyra Biosciences, Inc

• Product Description
• Research and Development
• Product Development Activities

Early Stage Products (Phase I)

• Comparative Analysis

UGN-301: UroGen Pharma Ltd.

• Product Description
• Research and Development
• Product Development Activities

Preclinical and Discovery Stage Products

• Comparative Analysis

Drug Name: Company Name

• Product Description
• Research and Development
• Product Development Activities

Inactive Products

• Comparative Analysis

Non Muscle Invasive Bladder Cancer Key Companies

Non Muscle Invasive Bladder Cancer Key Products

Non Muscle Invasive Bladder Cancer – Unmet Needs

Non Muscle Invasive Bladder Cancer – Market Drivers and Barriers

Non Muscle Invasive Bladder Cancer – Future Perspectives and Conclusion

Non Muscle Invasive Bladder Cancer Analyst Views

Non Muscle Invasive Bladder Cancer Key Companies

• CG Oncology
• Janssen Research & Development, LLC
• Tyra Biosciences, Inc
• UroGen Pharma Ltd.
• Prokarium Ltd
• Protara Therapeutics
• ImmVira Pharma Co. Ltd
• Trigone Pharma Ltd.
• Hoffmann-La Roche
• Aura Biosciences
• enGene Holdings Inc.
• Atonco Pharma

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/78gzrj

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Gateway to Growth: Innovation and Opportunity at the 8th CIIE




Gateway to Growth: Innovation and Opportunity at the 8th CIIE

SHANGHAI–(BUSINESS WIRE)–Amid a shifting global economy, the China International Import Expo (CIIE) continues to provide a vital gateway for global enterprises. With preparations for the 8^th CIIE well underway, the expo is set to once again showcase innovation, foster cooperation, and expand access to the Chinese dynamic market.

Leveraging the vital platform for global enterprises to access the Chinese massive market, many exhibitors have grown from participants into investors, while numerous exhibits have been transformed into marketable goods. Novartis, for instance, debuted Radioligand Therapy (RLT) at the 4^th CIIE. Benefiting from CIIE’s spillover effect, it signed strategic pacts with three Chinese partners—GE Healthcare China, Shanghai Pharmaceutical Holding and Chongqing Pharmaceutical Holding—at the 7^th CIIE to speed up RLT’s launch and expansion in China.

At the supply-demand matchmaking event of the 8^th CIIE, companies showcased 22 “CIIE Babies” —products that have successfully entered the market after their debut at previous expos, including two making their first post-launch appearance, underscoring the CIIE’s role in turning exhibits into goods. Medical innovations have also gained ground in China. Novartis built on its RLT debut last year by partnering with GE Healthcare China and others to create an RLT ecosystem. Meanwhile, Boston Scientific saw several products move from expo floor to market after the 7^th CIIE. Johnson & Johnson, expanding its booth to 700 square meters this year, will feature the MONARCH surgical robot and the lung cancer therapy Rukobia^®.

In parallel with the 8^th CIIE, this year’s Hongqiao International Economic Forum (HQF) unveiled its theme “Opening Up for New Opportunities, Collaborating for a Shared Future”. As a premier platform for global economic dialogue, the 8^th HQF will feature more than 20 sessions on Opening-up for Cooperation, Innovation, Development and Sharing. Preparations are in full swing, with active participation from international bodies like UNICEF and UNIDO, alongside government officials and industry leaders. The release of the World Openness Report 2025 will be a spotlight of the 8^th HQF, underscoring its role as a key platform for global dialogue and collaboration.

Don’t miss the chance to be part of this global event. The 8^th CIIE offers unparalleled opportunities for businesses to connect, innovate, and grow. Visit https://www.ciie.org/zbh/en/ for the latest updates and participation details.

Contacts

CUI Yan, cuiyan@sinoexpo.cc

Spasticity Pipeline Market Analysis Report 2025 | Comprehensive Insights on 10+ Companies and 12+ Pipeline Drugs – ResearchAndMarkets.com




Spasticity Pipeline Market Analysis Report 2025 | Comprehensive Insights on 10+ Companies and 12+ Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Spasticity – Pipeline Insight, 2025” clinical trials has been added to ResearchAndMarkets.com’s offering.

This “Spasticity – Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Spasticity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Spasticity pipeline landscape is provided which includes the disease overview and Spasticity treatment guidelines. The assessment part of the report embraces, in depth Spasticity commercial assessment and clinical assessment of the pipeline products under development.

In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Spasticity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Spasticity: Pipeline Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Spasticity therapeutic drugs key players involved in developing key drugs.

Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spasticity drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Spasticity R&D. The therapies under development are focused on novel approaches to treat/improve Spasticity.

Spasticity Emerging Drugs Chapters

This segment of the Spasticity report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Spasticity Emerging Drugs

MTR-601: Motric Bio

MTR-601, represents a potential first-in-class antispastic therapy with a unique mechanism of action that directly targets the contractile protein – myosin 2 – in fast-twitch skeletal muscle. As an oral, selective inhibitor, MTR-601 is designed to offer a non-invasive approach for the treatment of cervical dystonia, targeting fast-twitch muscle fibers with the potential to decrease stiffness and potentially improve physical function. MTR-601 on a robust body of preclinical data that demonstrates initial activity in selectively relaxing fast-twitch skeletal muscle subtypes. In a preclinical model, MTR-601 was also shown to improve gait function in spastic cerebral palsy. Currently, the drug is in Phase II stage of its development for the treatment of Spasticity.

IPN10200: Ipsen

IPN10200 is a long-acting botulinum neurotoxin candidate developed by Ipsen for the treatment of upper limb spasticity. Engineered for extended duration of effect, it aims to provide sustained relief from muscle hyperactivity by inhibiting acetylcholine release at neuromuscular junctions. As a targeted neurotoxin therapy, IPN10200 is designed to reduce muscle tone more consistently over time, potentially reducing injection frequency and improving patient convenience. Its development reflects Ipsen’s strategic focus on neuroscience and its commitment to advancing innovative therapeutic options in spasticity management. Currently, the drug is in Phase I/II stage of its development for the treatment of Spasticity.

Spasticity: Therapeutic Assessment

Major Players in Spasticity

There are approx. 10+ key companies which are developing the therapies for Spasticity. The companies which have their Spasticity drug candidates in the most advanced stage, i.e. Phase II include, Motric Bio.

Phases

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of:
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Spasticity Report Insights

• Spasticity Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Spasticity Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

• How many companies are developing Spasticity drugs?
• How many Spasticity drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Spasticity?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Spasticity therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Spasticity and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Motric Bio
• Ipsen
• Saol Therapeutics Inc
• Elpida Therapeutics SPC
• Celgene
• Tris Pharma, Inc.

Key Products

• MTR-601
• IPN10200
• SL-1002
• MELPIDA
• BMS-986368
• TRN-213

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/o72tb7

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Corneal Ulcer Market Research Report 2025-2035 | Overview and Ecosystem, Epidemiology, Key Trends, Impact Analysis, Regulatory Landscape, Pipeline Analysis, Market Dynamics – ResearchAndMarkets.com




Corneal Ulcer Market Research Report 2025-2035 | Overview and Ecosystem, Epidemiology, Key Trends, Impact Analysis, Regulatory Landscape, Pipeline Analysis, Market Dynamics – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Corneal Ulcer Market – A Global and Regional Analysis: Focus on Drug Class and Region – Analysis and Forecast, 2025-2035” report has been added to ResearchAndMarkets.com’s offering.

The corneal ulcer treatment market is poised for significant growth, driven by advancements in novel therapies, including regenerative treatments and targeted drug delivery systems. As awareness of corneal ulcers continues to rise, particularly in regions with high rates of contact lens usage and microbial infections, demand for effective treatments is expected to grow.

Additionally, improved healthcare infrastructure, especially in emerging markets, will enhance accessibility to advanced care. The growing focus on personalized medicine, combined with favourable reimbursement policies, will further support market expansion. With continued patient education and the development of innovative, more effective therapies, the corneal ulcer treatment market is well-positioned to address the rising need for specialized and targeted treatment options.

Growth in the corneal ulcer treatment market is supported by the increasing recognition of the condition’s impact on patients’ quality of life, especially due to its potential to lead to blindness if untreated. The market is evolving as healthcare providers and pharmaceutical companies focus on early diagnosis and intervention, offering a broader range of treatment options to improve patient outcomes and reduce recurrence of infections. Key therapeutic categories include topical antibiotics, antivirals, antifungals, corticosteroids, and regenerative therapies such as platelet-rich plasma (PRP) and recombinant human nerve growth factors, which are gaining attention for their potential to accelerate corneal healing and improve recovery rates.

Improved healthcare infrastructure in emerging markets, rising awareness among patients, and enhanced access to treatment are significant contributors to market growth. Furthermore, favourable reimbursement policies in developed regions are enabling greater access to advanced treatments, which further drives market expansion. The ongoing development of more targeted therapies and personalized treatment approaches, especially for patients with chronic or recurrent corneal ulcers, is expected to open new opportunities for market growth.

Advancements in drug delivery technologies, such as sustained-release ocular implants, nanoparticle-based therapies, and innovative eye drops, are playing a crucial role in expanding the therapeutic landscape for corneal ulcers. These innovations are designed to improve drug bioavailability, enhance treatment adherence, and minimize side effects, which are key challenges in the current treatment regimen. Additionally, personalized medicine, which takes into account individual patient profiles and genetic factors, is poised to revolutionize the management of corneal ulcers by offering more precise and effective treatment options.

Despite the promising growth prospects, the corneal ulcer market faces several challenges, including the high cost of advanced treatments, limited availability of specialized ophthalmologists, and inconsistent patient adherence to long-term treatment regimens. Moreover, the complex nature of microbial infections and the emergence of antibiotic-resistant pathogens complicate treatment efforts and may limit the effectiveness of current therapies. Regulatory hurdles and lengthy approval timelines for new treatments may also delay the availability of breakthrough therapies, further impacting market dynamics.

The competitive landscape of the corneal ulcer treatment market is characterized by the active involvement of leading pharmaceutical companies, biotechnology firms, and research institutions. Strategic partnerships, mergers, and acquisitions are common as stakeholders seek to enhance their product portfolios and accelerate research into more effective treatments. Investments in research and development, particularly in regenerative therapies, drug delivery systems, and novel antimicrobial agents, will play a key role in shaping the future of the market, aiming to improve clinical efficacy and provide better patient-centric care.

Looking forward, the global corneal ulcer treatment market is poised to continue its growth, driven by the rising incidence of corneal infections, advancements in treatment modalities, and a growing emphasis on patient education and disease prevention. The integration of digital health technologies, such as mobile apps for tracking treatment progress and remote consultations, is expected to improve treatment adherence and facilitate better disease management. With continued focus on personalized medicine and the development of more innovative therapeutic options, the corneal ulcer market is positioned to enhance patient outcomes and quality of life, providing a brighter future for those affected by this debilitating condition worldwide.

Competitive Landscape

• AbbVie Inc. (Allergan plc)
• Baxter International Inc.
• Bayer AG
• Dr. Reddy’s Laboratories Ltd.
• Eli Lilly and Company
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

Key Topics Covered:

1. Global Corneal Ulcer Market: Industry Analysis

• 1.1 Market Overview and Ecosystem
• 1.2 Epidemiological Analysis
• 1.3 Key Market Trends
• 1.3.1 Impact Analysis
• 1.4 Regulatory Landscape
• 1.5 Pipeline Analysis
• 1.6 Market Dynamics
• 1.6.1 Overview
• 1.6.2 Market Drivers
• 1.6.3 Market Restraints
• 1.6.4 Market Opportunities

2. Global Corneal Ulcer Market (by Drug Class), Value ($million), 2023-2035

• 2.1 Antibiotics
• 2.2 Antifungals
• 2.3 Antivirals
• 2.4 Corticosteroids
• 2.5 Others

3. Global Corneal Ulcer Market (by Region), Value ($Million), 2023-2035

• 3.1 North America
• 3.1.1 Market Dynamics
• 3.1.2 Market Sizing and Forecast
• 3.1.3 North America Corneal Ulcer Market, by Country ($Million), 2023-2035
• 3.1.3.1 U.S.
• 3.1.3.2 Canada
• 3.2 Europe
• 3.2.1 Market Dynamics
• 3.2.2 Market Sizing and Forecast
• 3.2.3 Europe Corneal Ulcer Market, by Country ($Million), 2023-2035
• 3.2.3.1 U.K.
• 3.2.3.2 France
• 3.2.3.3 Germany
• 3.2.3.4 Italy
• 3.2.3.5 Spain
• 3.2.3.6 Rest-of-Europe
• 3.3 Asia-Pacific
• 3.3.1 Market Dynamics
• 3.3.2 Market Sizing and Forecast
• 3.3.3 Asia-Pacific Corneal Ulcer Market, by Country ($Million), 2023-2035
• 3.3.3.1 Japan
• 3.3.3.2 China
• 3.3.3.3 India
• 3.3.3.4 Australia
• 3.3.3.5 South Korea
• 3.3.3.6 Rest-of-Asia-Pacific
• 3.4 Rest-of-the-World
• 3.4.1 Market Dynamics
• 3.4.2 Market Sizing and Forecast Rest-of-the-World Corneal Ulcer Market, by Type ($Million), 2023-2035
• 3.4.3 Rest-of-the-World Corneal Ulcer Market, by Country ($Million), 2023-2035
• 3.4.3.1 Latin America
• 3.4.3.2 Middle East and Africa

4. Competitive Landscape and Company Profiles

• 4.1 Competitive Landscape
• 4.1.1 Mergers and Acquisitions
• 4.1.2 Partnership, Alliances and Business Expansion
• 4.1.3 New Offerings
• 4.1.4 Regulatory Activities
• 4.1.5 Funding Activities
• 4.2 Company Profiles
• 4.2.1 Overview
• 4.2.2 Top Products / Product Portfolio
• 4.2.3 Top Competitors
• 4.2.4 Target Customers/End-Users
• 4.2.5 Key Personnel
• 4.2.6 Analyst View

5. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/mlqff0

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Dyslipidemia Market Research Report 2025-2035 | Expansion Fueled by Rising Cardiovascular Disease Burden, Lifestyle Risks, Early Diagnostics, and Preventive Health Initiatives – ResearchAndMarkets.com




Dyslipidemia Market Research Report 2025-2035 | Expansion Fueled by Rising Cardiovascular Disease Burden, Lifestyle Risks, Early Diagnostics, and Preventive Health Initiatives – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Dyslipidemia Market – A Global and Regional Analysis: Focus on Drug Class, Route of Administration, and Region – Analysis and Forecast, 2025-2035” report has been added to ResearchAndMarkets.com’s offering.

Dyslipidemia, characterized by abnormal levels of lipids such as cholesterol and triglycerides in the blood, significantly elevates the risk of cardiovascular diseases. Advances in lipid profiling, genetic testing, and risk assessment tools are enabling earlier and more precise diagnosis, thereby boosting demand for personalized therapeutic interventions. Statins remain the cornerstone of treatment, with newer drug classes such as PCSK9 inhibitors and RNA-based therapies gaining traction due to their efficacy in managing resistant cases.

However, challenges including patient non-compliance, side effects associated with long-term statin use, and high costs of novel therapies limit broader market penetration, especially in low and middle-income countries. Additionally, variations in treatment guidelines and healthcare infrastructure disparities complicate standardized care delivery. Nonetheless, growing government health initiatives, increased investment in cardiovascular research, and expanding awareness campaigns are driving improved screening and treatment rates.

Impact

Technological advancements in lipid diagnostics, genetic screening, and telemedicine platforms are significantly enhancing the early detection and personalized management of dyslipidemia. Innovations such as advanced lipid profiling, AI-driven risk prediction models, and wearable cardiovascular monitoring devices are improving the precision of disease assessment and treatment customization. Additionally, the integration of digital therapeutics and remote patient management is expanding access to care, particularly in underserved or rural areas, enabling continuous monitoring and better adherence to lipid-lowering therapies.

Statins hold the highest market share in the dyslipidemia market due to their proven efficacy, safety profile, and widespread clinical adoption as the first-line therapy for lowering LDL cholesterol and reducing cardiovascular risk. Extensive clinical trial evidence supports statins’ ability to significantly decrease morbidity and mortality associated with dyslipidemia-related conditions, which has solidified their position as the gold standard treatment globally.

Oral administration holds the highest market share in the dyslipidemia market, primarily because the majority of lipid-lowering drugs, including statins, fibrates, niacins, bile acid resins, and omega-3 fatty acids, are formulated for oral use. Oral medications offer greater patient convenience, ease of administration, and higher compliance compared to parenteral routes.

North America holds the highest market share in the dyslipidemia market, driven by its advanced healthcare infrastructure, high prevalence of cardiovascular diseases, and widespread adoption of lipid-lowering therapies. The region benefits from strong healthcare spending, well-established reimbursement frameworks, and early access to innovative treatments such as PCSK9 inhibitors.

How can this report add value to an organization?

Product/Innovation: This report provides comprehensive insights into the current trends in dyslipidemia, helping companies identify opportunities for drug and technology development. Organizations can leverage these insights to design therapies, medications, and platforms tailored to the needs of patients suffering from dyslipidemia, improving outcomes and enhancing market penetration.

Competitive: A detailed competitive landscape analysis helps organizations benchmark their market standing against key players. By understanding the strengths and weaknesses of competitors, companies can position themselves more effectively in the global dyslipidemia market.

Demand Drivers and Limitations

Drivers for the Global Dyslipidemia Market:

• Increasing cases of heart disease and stroke worldwide drive demand for effective lipid-lowering treatments.
• Lifestyle changes leading to obesity and diabetes contribute to higher dyslipidemia rates, boosting market growth
• Improved lipid profiling and genetic testing facilitate early diagnosis, increasing treatment uptake
• Public health initiatives promote regular cholesterol screening, leading to earlier intervention and therapy adoption

Limitations for the Global Dyslipidemia Market:

• Long-term medication adherence is often poor due to side effects and lack of symptom awareness, limiting treatment effectiveness
• Expensive drugs such as PCSK9 inhibitors restrict accessibility, especially in low- and middle-income countries.
• Adverse effects such as muscle pain and liver issues lead to discontinuation or reluctance in therapy initiation.

Key Market Players

• Amgen Inc.
• Sanofi S.A.
• Regeneron Pharmaceuticals, Inc.
• Pfizer Inc.
• Novartis AG
• Viatris Inc.
• AbbVie Inc.
• AstraZeneca plc
• Horizon Therapeutics plc
• Esperion Therapeutics, Inc.

Key Topics Covered:

1. Global Dyslipidemia Market: Industry Analysis

• 1.1 Market Overview and Ecosystem
• 1.2 Epidemiological Analysis
• 1.3 Key Market Trends
• 1.3.1 Impact Analysis
• 1.4 Regulatory Landscape
• 1.5 Pipeline Analysis
• 1.6 Market Dynamics
• 1.6.1 Overview
• 1.6.2 Market Drivers
• 1.6.3 Market Restraints
• 1.6.4 Market Opportunities

2. Global Dyslipidemia Market (by Drug Class), Value ($million), 2023-2035

• 2.1 Statins
• 2.2 Bile Acid Resins
• 2.3 Fibrates
• 2.4 Niacins
• 2.5 Omega-3 Fatty Acids
• 2.6 Others

3. Global Dyslipidemia Market (by Route of Administration), Value ($million), 2023-2035

• 3.1 Oral
• 3.2 Parenteral

4. Global Dyslipidemia Market (by Region), Value ($Million), 2023-2035

• 4.1 North America
• 4.1.1 Market Dynamics
• 4.1.2 Market Sizing and Forecast
• 4.1.3 North America Dyslipidemia Market, by Country ($Million), 2023-2035
• 4.1.3.1 U.S.
• 4.1.3.2 Canada
• 4.2 Europe
• 4.2.1 Market Dynamics
• 4.2.2 Market Sizing and Forecast
• 4.2.3 Europe Dyslipidemia Market, by Country ($Million), 2023-2035
• 4.2.3.1 U.K.
• 4.2.3.2 France
• 4.2.3.3 Germany
• 4.2.3.4 Italy
• 4.2.3.5 Spain
• 4.2.3.6 Rest-of-Europe
• 4.3 Asia-Pacific
• 4.3.1 Market Dynamics
• 4.3.2 Market Sizing and Forecast
• 4.3.3 Asia-Pacific Dyslipidemia Market, by Country ($Million), 2023-2035
• 4.3.3.1 Japan
• 4.3.3.2 China
• 4.3.3.3 India
• 4.3.3.4 Australia
• 4.3.3.5 South Korea
• 4.3.3.6 Rest-of-Asia-Pacific
• 4.4 Rest-of-the-World
• 4.4.1 Market Dynamics
• 4.4.2 Market Sizing and Forecast Rest-of-the-World Dyslipidemia Market, by Type ($Million), 2023-2035
• 4.4.3 Rest-of-the-World Dyslipidemia Disorder Market, by Country ($Million), 2023-2035
• 4.4.3.1 Latin America
• 4.4.3.2 Middle East and Africa

5. Competitive Landscape and Company Profiles

• 5.1 Competitive Landscape
• 5.1.1 Mergers and Acquisitions
• 5.1.2 Partnership, Alliances and Business Expansion
• 5.1.3 New Offerings
• 5.1.4 Regulatory Activities
• 5.1.5 Funding Activities
• 5.2 Company Profiles
• 5.2.1 Overview
• 5.2.2 Top Products / Product Portfolio
• 5.2.3 Top Competitors
• 5.2.4 Target Customers/End-Users
• 5.2.5 Key Personnel
• 5.2.6 Analyst View

6. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/htp9qf

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Chronic Inducible Urticaria (CIndU) Market Analysis Report 2025-2035 | Growth Driven by Rising Awareness, Immune Mechanism Insights, and Advancements in Biologic Therapies – ResearchAndMarkets.com




Chronic Inducible Urticaria (CIndU) Market Analysis Report 2025-2035 | Growth Driven by Rising Awareness, Immune Mechanism Insights, and Advancements in Biologic Therapies – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Chronic Inducible Urticaria Market – A Global and Regional Analysis: Focus on Drug Class and Region – Analysis and Forecast, 2025-2035” report has been added to ResearchAndMarkets.com’s offering.

The chronic inducible urticaria (CIndU) market is positioned for significant growth, driven by advancements in biologic therapies, targeted immunomodulatory treatments, and improved diagnostic tools that enhance the identification and management of this chronic skin condition. As awareness of CIndU increases, particularly regarding its diverse triggers such as cold, heat, and pressure, there is a growing demand for personalized treatment options tailored to individual triggers and immune profiles.

The rising prevalence of autoimmune and allergic conditions, combined with more widespread understanding of CIndU, is fuelling greater demand for effective therapies. Expanding healthcare access, especially in emerging markets with improving medical infrastructures, is expected to drive market growth. Furthermore, evolving reimbursement policies and the integration of precision medicine, which includes biomarker-based risk stratification and tailored treatment regimens.

Market growth is primarily driven by a deeper understanding of the disease’s underlying immune mechanisms, particularly its links to mast cell activation and immune system dysregulation. As awareness of CIndU increases among healthcare providers, especially in high-risk groups or patients with recurrent hives or unexplained allergic reactions, the demand for targeted treatments is set to rise. This is further accelerated by advancements in biologic therapies, particularly monoclonal antibodies such as omalizumab, which have shown promise in managing chronic spontaneous urticaria and are now being studied for CIndU.

Emerging diagnostic tools, including skin prick tests, cold stimulation tests, and electrodermal activity monitoring, are playing a key role in improving the speed and accuracy of diagnosis, reducing the time to treatment. Additionally, molecular diagnostics and biomarkers that identify specific triggers and immune profiles in patients are expected to further personalize and enhance treatment strategies. The evolution of these diagnostic modalities is allowing healthcare professionals to better identify and treat CIndU, leading to more effective management and improved patient outcomes.

Therapeutic strategies for CIndU are expanding, with antihistamines remaining the first-line treatment, complemented by biologic therapies and immunosuppressants for patients with moderate to severe disease. The increasing use of biologics, including omalizumab and dupilumab, which target key pathways involved in urticaria, is expected to significantly improve the quality of life for patients suffering from chronic urticaria. These biologics have shown clinical promise by reducing the frequency and severity of hives, and they represent a new era of treatment that is increasingly gaining traction.

Healthcare policy improvements, including better reimbursement frameworks for biologics and newer treatments, are driving market expansion. This is particularly evident in regions such as North America and Europe, where access to advanced therapies is improving. Additionally, updated clinical practice guidelines from organizations such as the American Academy of Dermatology (AAD) and the European Academy of Allergy and Clinical Immunology (EAACI) are promoting earlier and more proactive treatment strategies for CIndU, increasing patient access to specialized care and expanding eligibility for biologic therapies.

Technological advancements in patient monitoring and digital health are playing a growing role in the management of CIndU. Digital tools such as mobile apps that track symptoms and triggers, as well as telemedicine platforms that provide remote consultations, are enabling patients to better manage their disease on a day-to-day basis. These innovations also support long-term management by helping both patients and healthcare providers keep track of flare-ups, identify environmental triggers, and adhere to prescribed treatments.

However, the chronic inducible urticaria market faces several challenges. One of the most significant barriers is the lack of awareness about the condition, which often leads to delays in diagnosis and treatment. Given that CIndU is frequently misunderstood or misdiagnosed as other types of urticaria or allergic reactions, patients may suffer for years before receiving the appropriate treatment. Additionally, while antihistamines and corticosteroids provide relief, they often fall short for more severe cases, leaving a gap in effective treatment for a subset of patients. Furthermore, cost-related challenges, particularly for biologic therapies, limit access for certain patient groups, especially in developing regions or low-income populations.

Another challenge is the heterogeneity of the disease, with different forms of CIndU triggered by diverse physical stimuli. This variability complicates treatment protocols, as a single approach may not be effective for all patients. The lack of a one-size-fits-all treatment means that a personalized treatment approach will become increasingly important, but also more complex to implement.

The competitive landscape in the chronic inducible urticaria market is becoming more dynamic, with increased interest from pharmaceutical companies, biotechnology firms, and research institutions. Collaborations and strategic partnerships are accelerating the development of novel therapies and diagnostics. Companies are focusing on biologic treatments, monoclonal antibodies, and targeted immunotherapies, while also exploring new ways to deliver these treatments more efficiently.

Looking forward, the chronic inducible urticaria market is expected to continue its growth trajectory, fuelled by technological advancements, growing awareness, and the development of new therapeutic strategies. The integration of precision medicine, including molecular diagnostics, will play a central role in improving patient outcomes and refining treatment approaches. With a more personalized and proactive approach to care, CIndU patients are likely to experience better disease management and improved quality of life. The future of CIndU treatment holds promise with the ongoing clinical development of new biologics, digital health tools, and advanced therapies that aim to address the unmet needs of this patient population.

Companies Featured

• AstraZeneca
• Celldex Therapeutics, Inc.
• Johnson & Johnson Private Limited
• Merck & Co, Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals
• Sanofi
• Sun Pharmaceutical Industries Ltd.

Key Topics Covered:

1. Global Chronic Inducible Urticaria Market: Industry Analysis

1.1 Market Overview and Ecosystem

1.2 Epidemiological Analysis

1.3 Key Market Trends

1.3.1 Impact Analysis

1.4 Patent Analysis

1.4.1 Patent Filing Trend (by Country)

1.4.2 Patent Filing Trend (by Year)

1.5 Regulatory Landscape

1.6 Pipeline Analysis

1.7 Market Dynamics

1.7.1 Overview

1.7.2 Market Drivers

1.7.3 Market Restraints

1.7.4 Market Opportunities

2. Global Chronic Inducible Urticaria Market (by Drug Class), Value ($million), 2023-2035

2.1 Antihistamines

2.2 Corticosteroids

2.3 Monoclonal Antibodies

2.4 PDE4 Inhibitors

3. Global Chronic Inducible Urticaria Market (by Region), Value ($Million), 2023-2035

3.1 North America

3.1.1 Market Dynamics

3.1.2 Market Sizing and Forecast

3.1.3 North America Chronic Inducible Urticaria Market, by Country ($Million), 2023-2035

3.1.3.1 U.S.

3.1.3.2 Canada

3.2 Europe

3.2.1 Market Dynamics

3.2.2 Market Sizing and Forecast

3.2.3 Europe Chronic Inducible Urticaria Market, by Country ($Million), 2023-2035

3.2.3.1 U.K.

3.2.3.2 France

3.2.3.3 Germany

3.2.3.4 Italy

3.2.3.5 Spain

3.2.3.6 Rest-of-Europe

3.3 Asia-Pacific

3.3.1 Market Dynamics

3.3.2 Market Sizing and Forecast

3.3.3 Asia-Pacific Chronic Inducible Urticaria Market, by Country ($Million), 2023-2035

3.3.3.1 Japan

3.3.3.2 China

3.3.3.3 India

3.3.3.4 Australia

3.3.3.5 South Korea

3.3.3.6 Rest-of-Asia-Pacific

3.4 Rest-of-the-World

3.4.1 Market Dynamics

3.4.2 Market Sizing and Forecast Rest-of-the-World Chronic Inducible Urticaria Market, by Type ($Million), 2023-2035

3.4.3 Rest-of-the-World Chronic Inducible Urticaria Market, by Country ($Million), 2023-2035

3.4.3.1 Latin America

3.4.3.2 Middle East and Africa

4. Competitive Landscape and Company Profiles

4.1 Competitive Landscape

4.1.1 Mergers and Acquisitions

4.1.2 Partnership, Alliances and Business Expansion

4.1.3 New Offerings

4.1.4 Regulatory Activities

4.1.5 Funding Activities

4.2 Company Profiles

4.2.1 Overview

4.2.2 Top Products / Product Portfolio

4.2.3 Top Competitors

4.2.4 Target Customers/End-Users

4.2.5 Key Personnel

4.2.6 Analyst View

5. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/d1o41u

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Tardive Dyskinesia Market Research 2025 | Drug Class, Route of Administration, and Regional Analysis and Forecasts, 2023-2035 – ResearchAndMarkets.com




Tardive Dyskinesia Market Research 2025 | Drug Class, Route of Administration, and Regional Analysis and Forecasts, 2023-2035 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Tardive Dyskinesia Market – A Global and Regional Analysis: Focus on Drug Class, Route of Administration, and Region – Analysis and Forecast, 2025-2035” report has been added to ResearchAndMarkets.com’s offering.

The global tardive dyskinesia (TD) treatment market is undergoing significant transformation, fuelled by the rising prevalence of psychiatric disorders, increased antipsychotic medication usage, growing clinical awareness of TD, and notable advancements in both pharmacological and digital therapeutic interventions. Tardive dyskinesia a persistent, often irreversible, movement disorder caused primarily by long-term use of dopamine receptor-blocking agents represents a major neuropsychiatric concern. The market has seen renewed interest as healthcare systems worldwide confront the complexities of treating movement disorders induced by medications intended to manage chronic psychiatric conditions.

TD’s increasing diagnosis rates are closely tied to heightened recognition among clinicians and public health authorities, particularly in high-burden countries with elevated prescriptions of antipsychotic and gastrointestinal medications. The disorder is most commonly seen in patients with schizophrenia, bipolar disorder, and major depressive disorder who are on long-term treatment regimens. Market growth is accelerated by the growing demand for therapies that can offer symptom mitigation, improved functional outcomes, and long-term safety, particularly in vulnerable populations such as the elderly, those with cognitive impairment, and individuals with multiple comorbidities.

A major catalyst for expansion is the widening availability and uptake of VMAT2 (vesicular monoamine transporter 2) inhibitors, especially valbenazine and deutetrabenazine, which have become first-line treatments due to their proven efficacy and tolerability profiles. These drugs have not only reshaped the therapeutic landscape, also opened doors for novel delivery mechanisms and formulations, including once-daily and sprinkle variants, designed for greater adherence and patient-centric care. In parallel, the growing exploration of non-dopaminergic targets, gene therapies, and neuromodulation techniques such as deep brain stimulation (DBS) and transcranial magnetic stimulation (TMS) are contributing to an expanding and increasingly diversified treatment pipeline.

Improved healthcare infrastructure, especially in emerging markets such as India, Brazil, and Southeast Asia, is allowing for broader diagnosis and treatment. These developments are complemented by rising public and professional awareness, alongside enhanced access to movement disorder specialists and psychiatric neurologists. Furthermore, the integration of digital health tools, such as AI-powered video diagnostics, symptom tracking apps, and remote teleconsultations, is modernizing how TD is monitored and managed across diverse healthcare settings.

Despite these growth drivers, the TD market faces several pressing challenges. These include the high cost of branded VMAT2 inhibitors, particularly in markets with limited or no insurance coverage, as well as uneven access to specialists in rural or low-income regions. Diagnostic variability remains a critical barrier, with many cases going undiagnosed or misclassified, especially when symptoms are subtle or overlap with other movement disorders. Additionally, concerns around long-term efficacy and side effect profiles, as well as the lack of validated biomarkers for early detection or treatment monitoring, hinder broader adoption of advanced therapeutics.

Looking forward, the global TD market is poised to maintain a strong growth trajectory, driven by rising clinical demand, innovative treatment modalities, and increased emphasis on patient-centered care. The integration of real-world evidence (RWE), precision medicine frameworks, and wearable technologies is expected to personalize therapy and improve clinical outcomes. In combination with expanded diagnostic infrastructure, enhanced clinician training, and policy-level prioritization of neurological disorders, the TD market holds the potential to significantly improve the lives of patients affected by this complex, medication-induced movement disorder.

Companies Featured

• AbbVie Inc.
• H. Lundbeck A/S
• Ipsen Pharma
• Luye Pharma Group
• Mitsubishi Tanabe Pharma Corporation
• Neurocrine Biosciences, Inc.
• SOM BIOTECH
• SteriMax Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

Key Topics Covered:

1. Global Tardive Dyskinesia Market: Industry Analysis

1.1 Market Overview and Ecosystem

1.2 Epidemiological Analysis

1.3 Key Market Trends

1.3.1 Impact Analysis

1.4 Regulatory Landscape

1.5 Pipeline Analysis

1.6 Market Dynamics

1.6.1 Overview

1.6.2 Market Drivers

1.6.3 Market Restraints

1.6.4 Market Opportunities

2. Global Tardive Dyskinesia Market (by Drug Class), Value ($million), 2023-2035

2.1 Atypical Antipsychotics

2.2 Tetrabenazine

2.3 Vesicular Monoamine Transporter (VMAT) Inhibitors

2.4 Others

3. Global Tardive Dyskinesia Market (by Route of Administration), Value ($million), 2023-2035

3.1 Injectable

3.2 Intravenous

3.3 Oral

4. Global Tardive Dyskinesia Market (by Region), Value ($Million), 2023-2035

4.1 North America

4.1.1 Market Dynamics

4.1.2 Market Sizing and Forecast

4.1.3 North America Tardive Dyskinesia Market, by Country ($Million), 2023-2035

4.1.3.1 U.S.

4.1.3.2 Canada

4.2 Europe

4.2.1 Market Dynamics

4.2.2 Market Sizing and Forecast

4.2.3 Europe Tardive Dyskinesia Market, by Country ($Million), 2023-2035

4.2.3.1 U.K.

4.2.3.2 France

4.2.3.3 Germany

4.2.3.4 Italy

4.2.3.5 Spain

4.2.3.6 Rest-of-Europe

4.3 Asia-Pacific

4.3.1 Market Dynamics

4.3.2 Market Sizing and Forecast

4.3.3 Asia-Pacific Tardive Dyskinesia Market, by Country ($Million), 2023-2035

4.3.3.1 Japan

4.3.3.2 China

4.3.3.3 India

4.3.3.4 Australia

4.3.3.5 South Korea

4.3.3.6 Rest-of-Asia-Pacific

4.4 Rest-of-the-World

4.4.1 Market Dynamics

4.4.2 Market Sizing and Forecast Rest-of-the-World Tardive Dyskinesia Market, by Type ($Million), 2023-2035

4.4.3 Rest-of-the-World Tardive Dyskinesia Market, by Country ($Million), 2023-2035

4.4.3.1 Latin America

4.4.3.2 Middle East and Africa

5. Competitive Landscape and Company Profiles

5.1 Competitive Landscape

5.1.1 Mergers and Acquisitions

5.1.2 Partnership, Alliances and Business Expansion

5.1.3 New Offerings

5.1.4 Regulatory Activities

5.1.5 Funding Activities

5.2 Company Profiles

5.2.1 Overview

5.2.2 Top Products / Product Portfolio

5.2.3 Top Competitors

5.2.4 Target Customers/End-Users

5.2.5 Key Personnel

5.2.6 Analyst View

For more information about this report visit https://www.researchandmarkets.com/r/p88rwx

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900